Morgan Stanley says Firmus could be worth as much as $128b
Morgan Stanley research values AI chip rental firm Firmus at up to $128 billion ahead of its planned IPO next month; four banks will manage the float.
Investor · 1 deal
Every published round Morgans took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| OncoRes Medical | Unnamed stage | 12 Feb 2026 | $27m | Participant | Brandon BioCatalyst, oncoresmedical.com, Brandon Capital portfolio, Radar Ventures portfolio |
Companies Morgans has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| OncoRes Medical | 12 Feb 2026 | 1 | 0 |
Fund closes reported for Morgans, as distinct from the investments it has made.
Companies Morgans has backed that another company then bought. An exit for the holding, not a deal Morgans did.
| Name | Role | Sources |
|---|---|---|
| Chris Titley | Broker (former) | Startup Daily |
| Chris Titley | Broker (former) | Startup Daily |
| John Polinelli | Head of Corporate Advisory (former) | Australian FinTech |
| Hugh Robertson | Senior Adviser | AFR Technology |
Stories naming Morgans. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Morgan Stanley research values AI chip rental firm Firmus at up to $128 billion ahead of its planned IPO next month; four banks will manage the float.
Street Talk reports Melbourne-based medical company Akeeko Medical is out raising capital for a kidney stone treatment, with stockbroker Hugh Robertson leading the effort and putting in personal money.
Future Secure AI's pre-listing round, led by Robin Khuda, Square Peg, Yarra Capital, Firetrail and Macquarie Asset Management, is nearing completion, with notes converting at a US$1.3 billion ceiling before an ASX float.
Weekly roundup: Constantinople raises $62.5m; Blackbird wraps fund six above $1b; Guardhouse buys Mobohubb; SCX.ai debuts on the ASX; plus seed rounds, exits and executive changes across the ecosystem.
Melbourne deep tech company Orivium is seeking a Series B to commercialise its metal extraction process and has appointed ex-Lenovo chief Bill Amelio as global CEO, with Morgans as lead manager.
Perth-based OncoRes Medical has secured $27 million from Brandon Capital's BB6 Fund, Morgans, Radar Ventures and others to advance its Elora breast-surgery imaging device through an Australian clinical trial toward FDA approval.
Also oncoresmedical.com
A weekly roundup of funding deals by Australian and New Zealand startups, spanning baked goods, retail, health AI, beverages, edtech, solar, legal tech, and Western Australian medical research grants.
Also Startup Daily
Sydney non-alcoholic beverage maker Hopr has secured $3 million from individual backers after venture capitalists declined to back the consumer brand, with funds earmarked for production, distribution and marketing.
Also Startup Daily
Weekly roundup of four Australian startup raises: Kismet's $20m seed extension, Primary's $3.5m seed round, Willed's $3m from Seven West Media, and East Forged's $1.5m from a Vietnamese agribusiness's venture arm.
Swyftx adds three directors to its board following Jason Titman's June appointment as CEO, with founders Alex Harper and Angus Goldman also on the newly constituted board.
Swoop Telecommunications and NodeOne are to list on the ASX via a $61.3 million reverse takeover with Stemify, backed by Tattarang and founders James Spenceley and Tony Grist, plus a planned $20 million raise.
Also ARN (ARNnet)
A personal lender preparing to list has drawn early institutional orders, with three local fund managers taking cornerstone roles and the book reportedly filled before the formal build opens.
Broker Morgans' pre-float research values lender MoneyMe between $127 million and $243 million ahead of a possible ASX listing, benchmarking it against peers Zip Co and Prospa.
Sunshine Heart has completed an A$9.5m rights issue, following a September placement of A$3.7m. Backers GBS Venture Partners and CM Capital took full entitlements plus shortfall; proceeds fund US trials and European approval.
Sunshine Heart has locked in A$3.7 million from US institutional investors via Summer Street, with a larger rights issue of up to A$11 million still planned pending shareholder backing at an October meeting.
Also GBS Ventures